|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Circulating predictive and diagnostic biomarkers for hepatitis B virus-associated hepatocellular carcinoma显示文摘Chronic hepatitis B virus(HBV) infected patients have an almost 100-fold increased risk to develop hepatocellular carcinoma(HCC). HCC is the fifth most common and third most deadly cancer worldwide. Up to 50% of newly diagnosed HCC cases are attributed to HBV infection. Early detection improves survival and can be achieved through regular screening. Six-monthly abdominal ultrasound, either alone or in combination with alphafetoprotein serum levels, has been widely endorsed for this purpose. Both techniques however yield limited diagnostic accuracy, which is not improved when they are combined. Alternative circulating or histological markers to predict or diagnose HCC are therefore urgently needed. Recent advances in systems biology technologies have enabled the identification of several new putative circulating biomarkers. Although results from studies assessing combinations of these biomarkers are promising, evidence for their clinical utility remains low. In addition, most of the studies conducted so far show limitations in design. Attention must be paid for instance to different ethnicities and different etiologies when studying biomarkers for hepatocellular carcinoma. This review provides an overview on the current understandings and recent progress in the field of diagnostic and predictive circulating biomarkers for hepatocellular carcinoma in chronically infected HBV patients and discusses the future prospects. | Stijn Van Hees Peter Michielsen Thomas Vanwolleghem | 2016 | World Journal of Gastroenterology2016，22，37： | 13 |
| 2 | 白血病的DKK1基因研究进展显示文摘大量研究证实,Dickkopf-1(DKK1)基因启动子区域甲基化改变与许多肿瘤性疾病的发生发展有关,它是通过与相应受体结合,阻断Wnt/β-catenin/TCF传导通路,抑制肿瘤细胞增殖和侵袭,诱导其凋亡。白血病是一类造血干细胞恶性克隆增殖性疾病,其发病机制被证实与Wnt信号通路的异常激活有密切关系。Wnt信号传导通路与造血干细胞的自我更新和增殖有关,它可调控细胞的生长、分化、迁移及血管发生,其表达受通路抑制基因的调节,如Dickkopf-1(DKK1)基因。白血病常出现DKK1基因甲基化修饰,使得DKK1基因下调或沉默,导致经典Wnt信号通路被激活,引起白血病的发生。针对DKK1基因出现了一些关于白血病治疗的研究,主要是诱导DKK1去甲基化。随着对DKK1表达和功能的深入研究,有可能在白血病早期诊断、治疗、预后预警等方面发挥重要的作用。现就上述内容的研究进展作一综述。 | 柳凤芝 王季石 朱红倩 | 2015 | 中国实验血液学杂志2015，23，4： | 3 |
| 3 | 血清DKK1水平在塞来昔布一线联合铂类化疗治疗晚期非小细胞肺癌随机对照研究中的临床意义显示文摘目的通过塞来昔布一线与铂类化疗联合治疗晚期非小细胞肺癌(NSCLC)的随机对照研究评价环氧合酶2(COX-2)抑制剂的抗肿瘤作用及安全性;通过治疗过程中血清DKK1的监测探讨COX-2抑制剂相关的作用机制及疗效预测因子。方法初治Ⅲ-Ⅳ期NSCLC患者81例,随机分为治疗(长春瑞滨/顺铂+塞来昔布)组及对照(长春瑞滨/顺铂)组。直至第4个疗程中和后随访病情进展。患者初次化疗前及化疗2个疗程后ELISA法检测血清DKK1水平。结果治疗组客观缓解率(ORR)为34.1%,对照组为15.0%,两组差异具有统计学意义(P<0.05),治疗组无进展生存期(PFS)略长,为6.3个月,对照组为5.9个月,但差异未达到统计学意义的显著性。治疗前两组患者血清DKK1水平均无差异,且分别与患者年龄、性别、病理分型、分期、吸烟状况和ECOG评分无统计学意义的相关性。化疗2个疗程后两组血清DKK1水平均呈现下降趋势,但治疗组血清DKK1的下降幅度明显大于对照组(中位降低值分别为37.58对2.83 pg/ml,P=0.01);治疗组治疗后血清DKK1水平明显低于治疗前(P<0.05),对照组治疗前后差异不明显。两组治疗前后血清DKK1水平均未发现与化疗疗效显著相关(P分别为0.908,0.730,0.515,0.413)。两组治疗前血清DKK1水平均未能与患者PFS呈现显著相关(P=0.090,0.890),但塞来昔布组化疗后血清DKK1的下降幅度与患者PFS显著相关(P=0.043)。结论 COX-2抑制剂塞来昔布一线联合化疗能改善疾病控制率,患者耐受性好。血清DKK1水平可能是预测塞来昔布治疗疗效及预后的潜在生物标志物,尚需要大样本的研究证实。 | 滕家俊 裴俊 韩宝惠 姜丽岩 钟华 顾爱琴 储天晴 | 2015 | 世界临床药物2015，36，6： | 3 |
| 4 | 原发性肝癌患者介入治疗前后血清Dickkopf-1表达变化显示文摘目的观察原发性肝癌患者介入治疗前后血清Dickkopf-l(DKKl)表达水平的变化。方法采用ELISA法,检测40例健康体检者(对照组)以及87例原发性肝癌患者介入治疗前后血清DKKl水平并进行比较。结果对照组与Ⅱ、Ⅲ期原发性肝癌患者血清DKK1水平比较差异有统计学意义(P<0.05);原发性肝癌患者介入治疗后血清DKK1水平与治疗前比较,差异有统计学意义(P<0.05)。结论 DKK1可以作为评价原发性肝癌疗效和预后的指标。 | 刘旭超 陈鹏 黄清秀 张木根 | 2014 | 实用癌症杂志2014，29，11： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员